Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

PurposeA systematic review and meta-analysis was conducted to synthesize the available data from clinical trials and assess the safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes (T2D) and obesity.MethodsA systematic search was conducted in three electr...

Full description

Bibliographic Details
Main Authors:	Qingyue Zeng, Jiao Xu, Xingyu Mu, Yi Shi, Hong Fan, Shuangqing Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-10-01
Series:	Frontiers in Endocrinology
Subjects:	dual agonists incretin based therapy tirzepatide type 2 diabetes obesity glucagon-like peptide-1 receptor agonists
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1214334/full

Similar Items

Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
by: Qingyue Zeng, et al.
Published: (2024-03-01)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
by: Baptist Gallwitz
Published: (2022-10-01)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
by: Enrique Z. Fisman, et al.
Published: (2021-11-01)

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
by: Alexandros Leonidas Liarakos, et al.
Published: (2023-07-01)

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
by: Alekya Devi Anala, et al.
Published: (2023-07-01)

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
by: Zhuqing Meng, et al.
Published: (2023-03-01)

Tirzepatide for type 2 diabetes
by: Sarah L Anderson, et al.
Published: (2023-08-01)

Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
by: Vivek P. Chavda, et al.
Published: (2022-07-01)

Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?
by: Razzaki TS, et al.
Published: (2022-09-01)

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
by: Rachel Sinha, et al.
Published: (2023-03-01)

Clinical Research Progress of Tirzepatide: a New Hypoglycemic Agent
by: ZHANG Lina, WANG Yan, ZHANG Kanghuai, LI Youjia
Published: (2023-05-01)

The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects
by: Jensen TL, et al.
Published: (2024-02-01)

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
by: Qian Zhou, et al.
Published: (2023-10-01)

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program
by: Stephen J. Nicholls, et al.
Published: (2024-02-01)

Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review
by: Bartłomiej Stachyra, et al.
Published: (2023-04-01)

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
by: Linong Ji, et al.
Published: (2022-12-01)

Tirzepatide – a new analogue of incretin hormones
by: Gabriela Anglart, et al.
Published: (2023-10-01)

Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
by: Syed Faizan Mehdi, et al.
Published: (2023-05-01)

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
by: Yumie Takeshita, et al.
Published: (2022-06-01)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01)

Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist
by: Rouchan Ali, et al.
Published: (2022-09-01)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
by: Awadhesh Kumar Singh
Published: (2014-01-01)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
by: Kugler AJ, et al.
Published: (2018-05-01)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
by: Han Na Jung, et al.
Published: (2022-03-01)

Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

Liraglutide; A New Hope for Obese Diabetics
by: Ajeet Kumar, et al.
Published: (2020-12-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)

Tirzepatide-induced ketoacidosis in non-diabetic patients
by: Pathan Mohamad Rafe Iqbal, et al.
Published: (2024-03-01)

Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis
by: Akira Mima, et al.
Published: (2023-03-01)

Organoprotective effects of glucagon-like peptide-1 receptor agonists with regard to findings of evidencebased cardiovascular safety studies
by: Yu. Sh. Khalimov, et al.
Published: (2020-01-01)

Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials
by: Yu Mi Kang, et al.
Published: (2019-08-01)

Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial
by: Aung Myat, et al.
Published: (2021-02-01)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
by: Takaaki Murakami, et al.
Published: (2020-11-01)

Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
by: Nicholas Chiu, et al.
Published: (2022-08-01)

Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01)

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01)

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
by: Ren Q, et al.
Published: (2022-10-01)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
by: Ekaterina V. Tikhonenko, et al.
Published: (2018-12-01)

Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
by: Mihaela-Simona Popoviciu, et al.
Published: (2023-06-01)

Efficacy of once‐daily glucagon‐like peptide‐1 receptor agonist lixisenatide as an add‐on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual‐level pooled analysis of phase III studies
by: Fuqiang Liu, et al.
Published: (2021-08-01)